BioNexus Gene Lab (BGLC) Non Operating Investment Income (2024 - 2025)

BioNexus Gene Lab (BGLC) reported Non Operating Investment Income of -$28256.0 for Q4 2025, up 83.72% on a YoY basis from -$15379.6 in Q4 2024, and down 219.01% sequentially from $23742.0 in Q2 2025.

BioNexus Gene Lab (BGLC) Non Operating Investment Income (2024 - 2025) Analysis & Trends

BioNexus Gene Lab (BGLC) has 2 years of Non Operating Investment Income data on file, last reported at -$28256.0 in Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Investment Income rose 83.72% year-over-year to -$28256.0; the trailing twelve-month figure through Mar 2026 stood at -$4514.0 (up 58.18% YoY), and the FY2024 full-year result was $69476.0, down 77.34% from the prior year.
  • Non Operating Investment Income retreated to -$28256.0 in Q4 2025, from $23742.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $88532.0 in Q2 2024 to a low of -$173607.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Linde 237.95 Bn 233.99 Bn 4.26 Bn -
2 Sherwin Williams 78.17 Bn 77.95 Bn 2.78 Bn -
3 Ecolab 76.02 Bn 75.37 Bn 1.85 Bn -
4 Air Products & Chemicals 66.38 Bn 65.43 Bn 987.40 Mn -
5 Ppg Industries 26.02 Bn 24.40 Bn 1.66 Bn -
6 LyondellBasell Industries 22.51 Bn 19.87 Bn 701.00 Mn -
7 Chemical & Mining Co Of Chile 19.70 Bn 15.83 Bn 778.60 Mn 275.90 Mn
8 International Flavors & Fragrances 19.51 Bn 18.95 Bn 1.02 Bn -
9 DuPont de Nemours 18.80 Bn 18.71 Bn 602.00 Mn -
10 BioNexus Gene Lab 2.82 Mn -1.14 Mn -790.00 -

Historic Data

Download Data
DateValue
Dec 31, 2025 -28,256.00
Dec 31, 2025 -28,256.00
Jun 30, 2025 23,742.00
Jun 30, 2025 23,742.00
Mar 31, 2025 4,514.00
Mar 31, 2025 4,514.00
Dec 31, 2024 -173,607.00
Dec 31, 2024 -173,607.00
Sep 30, 2024 69,766.00
Sep 30, 2024 69,766.00
Jun 30, 2024 88,532.00
Jun 30, 2024 88,532.00
Mar 31, 2024 84,785.00
Mar 31, 2024 84,785.00